Jurkat-Human LAG-3 (Luc)-Reporter Cell

Introduction

The Jurkat-Human LAG-3 (Luc)-Reporter Cell is engineered to express the NFAT response element driving luciferase expression systems and the receptor full-length human LAG-3 (Uniprot: P18627-1), which can be used to evaluate the potency of LAG-3 blockade. When co-cultured with target cells expressing human MHCⅡ, the LAG-3/MHCⅡ interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the LAG-3/MHCⅡ interaction by anti-LAG-3 antibodies releases the inhibitory signals and results in TCR activation and NFAT-mediated luminescence.

Application

Screen for anti-human LAG-3 antibody.

Background

LAG-3 (Lymphocyte Activation Gene 3) is an inhibitory receptor expressed on activated T cells, NK cells, and B cells. It binds to MHC class II molecules and FGL1, delivering inhibitory signals that suppress T cell function. LAG-3 synergizes with PD-1 to promote T cell exhaustion in cancer and chronic infections.

Product Information